Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review
MG Del Buono, RA Montone, M Camilli… - Journal of the American …, 2021 - jacc.org
Coronary microvascular dysfunction (CMD) encompasses several pathogenetic
mechanisms involving coronary microcirculation and plays a major role in determining …
mechanisms involving coronary microcirculation and plays a major role in determining …
The aging cardiovascular system: understanding it at the cellular and clinical levels
Cardiovascular disease (CVD) presents a great burden for elderly patients, their caregivers,
and health systems. Structural and functional alterations of vessels accumulate throughout …
and health systems. Structural and functional alterations of vessels accumulate throughout …
[HTML][HTML] Angiotensin–neprilysin inhibition in acute decompensated heart failure
EJ Velazquez, DA Morrow, AD DeVore… - … England Journal of …, 2019 - Mass Medical Soc
Background Acute decompensated heart failure accounts for more than 1 million
hospitalizations in the United States annually. Whether the initiation of sacubitril–valsartan …
hospitalizations in the United States annually. Whether the initiation of sacubitril–valsartan …
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised …
Aims To assess tolerability and optimal time point for initiation of sacubitril/valsartan in
patients stabilised after acute heart failure (AHF). Methods and results TRANSITION was a …
patients stabilised after acute heart failure (AHF). Methods and results TRANSITION was a …
Sacubitril/valsartan across the spectrum of ejection fraction in heart failure
SD Solomon, M Vaduganathan, B L. Claggett… - Circulation, 2020 - Am Heart Assoc
Background: While disease-modifying therapies exist for heart failure (HF) with reduced left
ventricular ejection fraction (LVEF), few options are available for patients in the higher range …
ventricular ejection fraction (LVEF), few options are available for patients in the higher range …
[HTML][HTML] Angiotensin–neprilysin inhibition versus enalapril in heart failure
Background We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with
enalapril in patients who had heart failure with a reduced ejection fraction. In previous …
enalapril in patients who had heart failure with a reduced ejection fraction. In previous …
Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure
LB Arendse, AHJ Danser, M Poglitsch, RM Touyz… - Pharmacological …, 2019 - ASPET
Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT1R) blockers, current …
enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT1R) blockers, current …
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
JP Seferovic, B Claggett, SB Seidelmann… - The lancet Diabetes & …, 2017 - thelancet.com
Background Diabetes is an independent risk factor for heart failure progression.
Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves …
Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves …
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure
Background—Clinical trials in heart failure have focused on the improvement in symptoms
or decreases in the risk of death and other cardiovascular events. Little is known about the …
or decreases in the risk of death and other cardiovascular events. Little is known about the …
Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure
MR Zile, BL Claggett, MF Prescott… - Journal of the American …, 2016 - jacc.org
Background: Natriuretic peptides (NP) have prognostic value in heart failure (HF), although
the clinical importance of changes in NP from baseline is unclear. Objectives: The authors …
the clinical importance of changes in NP from baseline is unclear. Objectives: The authors …